Skip to content

Study · Randomized controlled trial · n = 9,340 · 2020

4 results

Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials.

Verma S, Bain SC, Honoré JB, F E Mann J, A Nauck M, E Pratley R, Rasmussen S, Sejersten Ripa M, Zinman B, Buse JB

Diabetes, obesity & metabolism12 Aug 2020Cited by 18 (Europe PMC)

PMID32643857 (opens in a new tab)PMCIDPMC7689837 (opens in a new tab)DOI10.1111/dom.14140 (opens in a new tab)PepBankPUB-32643857
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, liraglutide consistently reduced cardiovascular risk versus placebo in patients with and without microvascular disease.

    In plain wordsIn adults with type 2 diabetes, liraglutide lowered heart risk compared with placebo, both in people with and without small-vessel disease.

    Peptide
    Liraglutide
    Outcome
    DecreaseCardiovascular risk reduction with and without baseline microvascular disease
    Study

    n = 9,340

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    1.8 mgAs given in this study (human).

    Source sentences

    Summary
    Liraglutide and semaglutide consistently reduced cardiovascular risk in patients with and without microvascular disease.
    2 context sentences
    Summary · context
    the efficacy of liraglutide (1.8 mg) and once-weekly semaglutide (0.5-1.0 mg) in patients with and without microvascular disease.
    Summary · context
    In total, 9340 patients from LEADER and 3297 patients from SUSTAIN 6 were included in this analysis; of these, 5761 and 2356 had a history of microvascular disease at baseline and 3835 and 1640 had a history of both microvascular and macrovascular disease, respectively.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, semaglutide consistently reduced cardiovascular risk versus placebo in patients with and without microvascular disease.

    In plain wordsIn adults with type 2 diabetes, semaglutide lowered heart risk compared with placebo, both in people with and without small-vessel disease.

    Peptide
    Semaglutide
    Outcome
    DecreaseCardiovascular risk reduction with and without baseline microvascular disease
    Study

    n = 3,297

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    0.5-1.0 mg once weeklyAs given in this study (human).

    Source sentences

    Summary
    Liraglutide and semaglutide consistently reduced cardiovascular risk in patients with and without microvascular disease.
    2 context sentences
    Summary · context
    once-weekly semaglutide (0.5-1.0 mg) in patients with and without microvascular disease.
    Summary · context
    In total, 9340 patients from LEADER and 3297 patients from SUSTAIN 6 were included in this analysis; of these, 5761 and 2356 had a history of microvascular disease at baseline and 3835 and 1640 had a history of both microvascular and macrovascular disease, respectively.

Studies that did not test the peptide alone2

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 03HumanNot a test of Liraglutide aloneRandomized controlled trialOther

    In the LEADER trial of adults with type 2 diabetes, patients with microvascular disease at baseline had a higher risk of major adverse cardiovascular events than patients without it. This is a prognostic association, not a liraglutide effect.

    In plain wordsIn adults with type 2 diabetes, having small-vessel disease was linked to a higher risk of major heart events.

    Peptide
    Liraglutide
    Outcome
    IncreaseMACE risk with versus without baseline microvascular disease (LEADER)
    Study

    n = 9,340

    Comparator
    Patients without microvascular disease
    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    Hazard ratio
    1.15
    LEADER, microvascular disease vs none

    Source sentences

    Summary
    Patients with microvascular disease were shown to have an increased risk of major adverse cardiovascular events compared with patients without microvascular disease (hazard ratio [95% confidence interval] in LEADER: 1.15 [1.03; 1.29], P = .0136; SUSTAIN 6: 1.56 [1.14; 2.17], P = .0064).
    1 context sentence
    Summary · context
    In total, 9340 patients from LEADER and 3297 patients from SUSTAIN 6 were included in this analysis; of these, 5761 and 2356 had a history of microvascular disease at baseline and 3835 and 1640 had a history of both microvascular and macrovascular disease, respectively.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 04HumanNot a test of Semaglutide aloneRandomized controlled trialOther

    In the SUSTAIN 6 trial of adults with type 2 diabetes, patients with microvascular disease at baseline had a higher risk of major adverse cardiovascular events than patients without it. This is a prognostic association, not a semaglutide effect.

    In plain wordsIn adults with type 2 diabetes, having small-vessel disease was linked to a higher risk of major heart events.

    Peptide
    Semaglutide
    Outcome
    IncreaseMACE risk with versus without baseline microvascular disease (SUSTAIN 6)
    Study

    n = 3,297

    Comparator
    Patients without microvascular disease
    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    Hazard ratio
    1.56
    SUSTAIN 6, microvascular disease vs none

    Source sentences

    Summary
    Patients with microvascular disease were shown to have an increased risk of major adverse cardiovascular events compared with patients without microvascular disease (hazard ratio [95% confidence interval] in LEADER: 1.15 [1.03; 1.29], P = .0136; SUSTAIN 6: 1.56 [1.14; 2.17], P = .0064).
    1 context sentence
    Summary · context
    In total, 9340 patients from LEADER and 3297 patients from SUSTAIN 6 were included in this analysis; of these, 5761 and 2356 had a history of microvascular disease at baseline and 3835 and 1640 had a history of both microvascular and macrovascular disease, respectively.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01720446

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 3,29721 Feb 2013 to 15 Mar 2016

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 27 Jun 2019
CompletedPhase 3Results postedNCT01179048

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

Novo Nordisk A/Sn = 9,34131 Aug 2010 to 17 Dec 2015

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 17 Jul 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.